Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2022 16:15 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval applicationAllarity intends to seek guidance from the FDA on...
January 03, 2022 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity...
December 22, 2021 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...
December 21, 2021 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market

Press release Cambridge, MA U.S.A. (December 21, 2021) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology...
December 13, 2021 17:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North

Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”)...
December 11, 2021 09:35 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North

Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders...
November 24, 2021 17:15 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of...
November 24, 2021 15:50 ET | Source: Allarity Therapeutics A/S

Grant of New Warrants and Resolutions on Existing Warrants

Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the...
November 23, 2021 02:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Publishes Interim Report for the Period January – September 2021

Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September...
November 22, 2021 18:00 ET | Source: Allarity Therapeutics A/S

Minutes of Extraordinary General Meeting held on 22 November 2021

Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the...